Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitlePrior Cannabis Use Is Associated with Outcome after Intracerebral Hemorrhage.
Author(s)Di Napoli M, Zha AM, Godoy DA, Masotti L, Schreuder FH, Popa-Wagner A, Behrouz R; MNEMONICH Registry.
Journal, Volume, IssueCerebrovasc Dis. 2016;41(5-6):248-55. doi: 10.1159/000443532. Epub 2016 Jan 29.
Major outcome(s)Cannabinoids-positive patients had lower median disease scores on admission
IndicationAbstract
MedicationCannabis

OBJECTIVE: Recent evidence suggests that a potential harmful relationship exists between cannabis use and ischemic stroke. The purpose of this study was to determine the implications of cannabis use in intracerebral hemorrhage (ICH) patients. METHODS: An analysis of an international, multicenter, observational database of consecutive patients with spontaneous ICH was conducted. We extracted the following characteristics on presentation: demographics, risk factors, antiplatelet or anticoagulant use, Glasgow Coma Scale, ICH score, neuroimaging parameters, and urine toxicology screen (UTS) results. Modified Rankin Scale (mRS) score was utilized for determination of outcome at discharge. Adjusted logistic ordinal regression was used as shift analysis to assess the impact of cannabis use on mRS score at discharge. The adjusted common OR measured the likelihood that cannabis use would lead to lower mRS scores. RESULTS: Within a cohort of 725 spontaneous ICH patients, UTS was positive for cannabinoids in 8.6%. Cannabinoids-positive (CB+) patients were more frequently Caucasian (p < 0.001), younger (p < 0.001), and had lower median ICH scores on admission (p = 0.017) than those who were cannabinoids-negative. CB+ patients also showed a shift toward better outcome in the distribution of mRS categories, with an adjusted common OR of 0.544 (95% CI 0.330-0.895, p = 0.017). CONCLUSION: In this multinational cohort, cannabis use was discovered in nearly 10% of patients with spontaneous ICH. Although there was no relationship between cannabis use and specific ICH characteristics, CB+ patients had milder ICH presentation and less disability at discharge.

Route(s)
Dose(s)
Duration (days)
Participants725 patients with spontaneous bleeding in the brain
DesignOpen study
Type of publicationMedical journal
Address of author(s)Neurological Service, San Camillo de' Lellis General Hospital, Rieti, Italy.
Full texthttps://www.ncbi.nlm.nih.gov/pubmed/?term=26820826

[Back to Overview]  [IACM Homepage]


up